MedTrace Logo

Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer

NCT02512458 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-02-10

No results posted yet for this study

Summary

This is a prospective, open-label, single arm translational study of cabazitaxel in bone Castration Resistant metastatic Pancreatic Cancer (mCRPC) patients. Patient will be treated with intravenous (iv) cabazitaxel 25mg/m2 every (q) 21days per standard clinical practice for up to 10 cycles or until disease progression or unacceptable toxicity or physician's decision or patient's consent withdrawal (whichever occurs first).

Conditions

  • Bone Metastatic Prostate Cancer

Interventions

DRUG

Cabazitaxel

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Hellenic Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Eleni Efstathiou, MD,Ass. Prof · Unit of Medical Oncology,Department of Clinical Theraputics,General Hospital of Athens "Alexandra"

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-29
Primary Completion
2019-12-31
Completion
2019-12-27

Countries

  • Greece

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02512458 on ClinicalTrials.gov